A new report from the bipartisan US-China Economic and Security Review Commission is urging Congressional lawmakers not to ignore the impact of China’s growing influence on US drug development. It underscored that if the United States doesn’t respond quickly, there could be serious concerns for the domestic supply chain.
Free Trial
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day
